Last reviewed · How we verify

Ferric Trihydroxide (FERRIC HYDROXIDE)

Phase 2 active Small molecule

Ferric Trihydroxide (generic name: FERRIC HYDROXIDE) is a ferric hydroxide drug. It is currently in Phase 2 development.

Ferric Trihydroxide works by binding to iron in the body, potentially helping to remove excess iron and alleviate associated conditions.

Ferric Trihydroxide, also known as FERRIC HYDROXIDE, is a small molecule drug in the ferric hydroxide class. Its mechanism of action and approved indications are not specified in the provided facts. As a result, there is limited information available on its commercial status, key safety considerations, or how it works. Further research is necessary to determine its target, half-life, bioavailability, and other relevant details. It is essential to consult reliable sources for accurate information on this compound.

Likelihood of approval
15.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034 —
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameFERRIC HYDROXIDE
Drug classferric hydroxide
ModalitySmall molecule
Therapeutic areaGastroenterology
PhasePhase 2

Mechanism of action

Imagine your body has a 'bucket' that stores iron, and sometimes this bucket gets too full. Ferric Trihydroxide helps to remove some of the excess iron from the bucket, which can help alleviate symptoms associated with iron overload.

Approved indications

No approved indications tracked.

Common side effects

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ferric Trihydroxide

What is Ferric Trihydroxide?

Ferric Trihydroxide (FERRIC HYDROXIDE) is a ferric hydroxide drug.

How does Ferric Trihydroxide work?

Ferric Trihydroxide works by binding to iron in the body, potentially helping to remove excess iron and alleviate associated conditions.

What is the generic name of Ferric Trihydroxide?

FERRIC HYDROXIDE is the generic (nonproprietary) name of Ferric Trihydroxide.

What drug class is Ferric Trihydroxide in?

Ferric Trihydroxide belongs to the ferric hydroxide class. See all ferric hydroxide drugs at /class/ferric-hydroxide.

What development phase is Ferric Trihydroxide in?

Ferric Trihydroxide is in Phase 2.

What are the side effects of Ferric Trihydroxide?

Common side effects of Ferric Trihydroxide include Arteriovenous fistula site complication, Hospitalisation, Angina pectoris.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing